Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN III 10 versus LIPOSYN III 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN III 10 versus LIPOSYN III 20.
LIPOSYN III 10% vs LIPOSYN III 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposyn III 10% is an intravenous fat emulsion that provides essential fatty acids (linoleic and linolenic acids) and a source of calories. The triglycerides are hydrolyzed by lipoprotein lipase to free fatty acids and glycerol, which are then utilized for energy production or stored. The emulsion particles are metabolized similarly to endogenous chylomicrons.
Liposyn III 20% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories. It serves as a source of energy and prevents essential fatty acid deficiency by supplying triglycerides that are hydrolyzed to free fatty acids and glycerol for metabolism.
Intravenous infusion: 500 mL to 1000 mL per day, providing 10% lipid emulsion (100 g fat per liter), infused over 8-12 hours as part of parenteral nutrition, not to exceed 2.5 g fat/kg/day.
Adults: 500 mL to 2500 mL per day via continuous intravenous infusion (including peripheral or central vein); typical rate: 0.5-1 mL/kg/h initially, increasing to 1.5-2 mL/kg/h as tolerated. Maximum infusion rate: 2.5 mL/kg/h.
None Documented
None Documented
Triglycerides in Liposyn III 10% have a terminal elimination half-life of approximately 0.5 to 1 hour in patients with normal lipid metabolism. In neonates or hepatic impairment, half-life may be prolonged.
The terminal elimination half-life of infused triglycerides is approximately 0.5–1 h (33–60 min). Clearance is saturable; at high infusion rates, half-life may prolong.
Lipids are metabolized via hydrolysis by lipoprotein lipase into free fatty acids and glycerol. Free fatty acids undergo beta-oxidation or re-esterification. Elimination of CO2 via lungs; less than 5% excreted renally as glycerol and other metabolites.
Primarily eliminated via endogenous lipid metabolic pathways (beta-oxidation in tissues). <5% excreted unchanged in urine; minimal biliary/fecal elimination.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion